ArticleEuropean heart journal. Case reports2025
Anakinra during pregnancy and lactation for corticosteroid-dependant colchicine-resistant recurrent pericarditis in a patient with neutralizing anti-interleukin-1 receptor antagonist antibodies: a case report.
Article in European heart journal. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anakinra, an interleukin-1 receptor antagonist (IL-1 Ra), is a treatment option for recurrent pericarditis refractory to conventional therapy. However, some patients cannot discontinue anakinra treatment without relapse. This is of particular concern for women of childbearing age, as data on its safety during pregnancy and lactation is limited. Case summary: We report the case of a 36-year-old White woman with recurrent pericarditis of an inflammatory phenotype. Pericardial biopsy revealed virus-negative fibro-productive pericarditis, and genetic testing showed no identifiable cause. Despite treatment with non-steroidal anti-inflammatory drugs, colchicine, and corticosteroids, the patient experienced multiple recurrences and developed corticosteroid-related side effects. Introduction of anakinra resulted in immediate clinical improvement and allowed corticosteroid withdrawal. However, several attempts to discontinue anakinra led to pericarditis recurrences. The patient tested positive for neutralizing anti-IL-1Ra antibodies. During the stable phase of the disease, as confirmed by cardiac magnetic resonance imaging, and while on anakinra and colchicine, she conceived spontaneously. She maintained anakinra treatment throughout the full-term pregnancy and breastfeeding, with no impact on foetal or child development. Discussion: Our paper provides evidence supporting the safe use of anakinra in pregnancy and lactation in a patient with recurrent pericarditis. It also reports the first case of anti-IL-1Ra antibodies in a patient receiving anakinra for recurrent pericarditis, which may help explain the dependency on the medication. The potential role of these antibodies as biomarkers for anakinra dependency or tools for optimizing immunosuppressive treatment warrants further research. A patient-centred counselling and a multidisciplinary approach are essential for achieving optimal outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.